(image: Korea Bizwire)
LONDON and BANGKOK, Thailand, July 3 (Korea Bizwire) — Aztiq Pharma Partners (“Aztiq”), a private equity company focused on the life sciences sector, and Innobic (Asia) Company Limited (“Innobic”), the life science arm of Thai oil and gas conglomerate PTT Public Company Limited (“PTT”) (collectively, “the shareholders”), today announced the pricing of a sale of 25,095,850 shares of Lotus Pharmaceuticals (1795:TT; “Lotus,” “the company”), a multinational pharmaceutical company, at a price of NT$297 per share. The trade will be settled on July 5, 2023, subject to satisfaction of customary settlement procedures. The sale is being executed by Alvogen Emerging Market Holdings Limited (“AEMH”), which will continue to own 41% of Lotus common stock after the close of the transaction. Inclusive of Innobic’s direct holdings of Lotus, the shareholders will continue to own approximately 47.7% of the company.
Robert Wessman, Founder of Aztiq, commented: “Today’s announcement is a big step in the evolution of Lotus that started as a company whose business was nearly entirely domestic. The company today has evolved into a global pharmaceutical company with a vast portfolio of products and a global reach that touches nearly every corner of the world through the company’s export business or through Lotus’s own commercial infrastructure that spreads throughout Asia. As Chairman, I look forward to continuing to work with Lotus’ proven management team that has led this transformation to collaborate on strategy and grow the business going forward.”
Dr. Buranin Rattanasombat, Chief New Business and Infrastructure Officer of PTT, and Chairman of Innobic, commented: “This transaction is a significant step for Lotus as it concurrently increases free-float of the stock and diversifies the shareholder base with strong institutional investors. As a leading shareholder of Lotus, our interests remain truly aligned with those of the company and its valued shareholders.”
J.P. Morgan and Credit Suisse are acting as placing agents for the trade.
About Aztiq
Aztiq is a visionary healthcare focused private equity company dedicated to fostering innovation and driving positive change within the industry. Led by Robert Wessman and a team of veteran entrepreneurs, Aztiq is committed to identifying, investing in, and nurturing ground-breaking healthcare solutions in pharma and biotech to address global healthcare challenges. By leveraging the cumulative experience of the team, Aztiq aims to improve patient outcomes, increase access to quality healthcare, and create a more efficient and sustainable healthcare ecosystem. With a proven track record of success, Aztiq continues to make a lasting impact on the health and well-being of people around the world. For more information, please visit www.aztiq.com and follow Aztiq on LinkedIn.
About Innobic
Innobic (Asia) Company Limited is a wholly-owned subsidiary of PTT, the largest energy company in Thailand majority owned by Ministry of Finance Thailand and listed in Fortune Global 500. PTT has moved from a national energy provider to a multinational conglomerate and started to diversify the business into new sectors, including Life Science, Renewables, Electricity value chain, and Ventures, to serve as its new S-curve. It officially established Innobic in December 2020 for a strategic goal to building up a new footprint in Life Science fields for PTT Group, with an initial focus on pharmaceuticals, and aims to make Innobic become a leading Life Science company in the region to bring best science and enhance life qualify of people. For more information, please visit www.innobicasia.com
Media Enquiries:
Ming Li
+16465093032
ming.li@aztiq.com
Jaruchai Sutjarittam
+66888924564
Jaruchai.s@innobicasia.com
Source: Aztiq Consulting ehf. via GLOBE NEWSWIRE
